In the face of new variants and lower public acceptance of vaccination, it’s imperative that we take stock of lessons learned from previous seasons and examine key barriers to uptake as we prepare for this fall and winter – from adjusting approval timelines at the federal level, to implementing programs to address vaccine complacency, convenience and confidence.
The FDA has granted the Pfizer and BioNTech Covid-19 full approval for use in adolescents. In other Covid-19 news, pharmacists were granted additional prescribing powers for an antiviral and Novavax’s European marketing authorization has been expanded to an additional age group.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Because the virus keeps mutating and will be around for a long time, the market for Pfizer’s products won’t go away. In wealthier countries, the public is likely to keep coming back for more, like diners at an all-you-can-eat restaurant, sated but never entirely satisfied.
Covid-19 vaccines from Pfizer and Moderna now have FDA emergency use authorization for children as young as 6 months old. If the Centers for Disease Control and Prevention signs off on these shots this weekend, these pediatric vaccines could become available for distribution early next week.
Pictor is partnering with Mobility Health to distribute Pictor's novel Covid-19 antibody test, which can assess in one test if a person has antibodies to protect against Covid-19 and if that is due to infection or vaccination; Pictor also received a $6.1 million investment.
Two prominent Democratic senators - Robert Casey Jr. of Pennsylvania and Ron Wyden of Oregon - have requested a Government Accountability Office study of why covid vaccination rates remain far lower among Medicaid enrollees than the general population.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Vermont’s covid-related hospitalization rates, while higher than last winter’s peak, still rank last in the nation. And overall death rates also rank comparatively low.
The national effort to vaccinate children has stalled even as the omicron variant upends schooling for millions of children and their families amid staffing shortages, shutdowns and heated battles over how to safely operate.
New semiquantitative tests offer a more granular understanding of our protective immunity, not only identifying Covid-19 antibodies but providing direct, individualized measures of neutralizing antibody levels.
By automating patient engagement, these organizations can reduce the burden on both resources and personnel in fighting this pandemic while improving efficiency in the administration of booster vaccines.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
New recommendations may provide reassurance for patients and their care teams, while uniquely positioning healthcare providers to help communicate this critical information to vulnerable populations.
These next few months are a tremendous opportunity to build trust with customers — imagine the reciprocal goodwill if a payer’s message helps its members get to the front of the line.
With widespread vaccine shortages alongside continuing deaths from Covid-19, we must act now to leverage existing technology in order to improve the distribution process.
To counter vaccine hesitancy, especially dominant in at-risk communities, we need hyper-local and population-specific vaccine programs.
The vaccine is being delivered to 195 countries with different databases healthcare systems. Healthtech solutions help us bring together data from different healthcare organizations, manufacturing and distributing facilities, and government departments into a centralized location.